La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Evaxion Biotech Résultats passés
Passé contrôle des critères 0/6
Evaxion Biotech's earnings have been declining at an average annual rate of -7.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 155.2% per year.
Informations clés
-7.3%
Taux de croissance des bénéfices
9.0%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 155.2% |
| Rendement des fonds propres | -1,213.5% |
| Marge nette | -5,469.4% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Ventilation des recettes et des dépenses
Comment Evaxion Biotech gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -15 | 9 | 11 |
| 31 Mar 24 | 0 | -15 | 9 | 11 |
| 31 Dec 23 | 0 | -22 | 10 | 12 |
| 30 Sep 23 | 0 | -24 | 11 | 14 |
| 30 Jun 23 | 0 | -25 | 10 | 15 |
| 31 Mar 23 | 0 | -24 | 9 | 16 |
| 31 Dec 22 | 0 | -23 | 8 | 17 |
| 30 Sep 22 | 0 | -25 | 7 | 19 |
| 30 Jun 22 | 0 | -24 | 7 | 19 |
| 31 Mar 22 | 0 | -26 | 7 | 20 |
| 31 Dec 21 | 0 | -25 | 6 | 20 |
| 30 Sep 21 | 0 | -20 | 6 | 16 |
| 30 Jun 21 | 0 | -19 | 7 | 15 |
| 31 Mar 21 | 0 | -16 | 6 | 12 |
| 31 Dec 20 | 0 | -15 | 6 | 11 |
| 30 Sep 20 | 0 | -14 | 5 | 11 |
| 31 Dec 19 | 0 | -11 | 3 | 8 |
Des revenus de qualité: EVAX is currently unprofitable.
Augmentation de la marge bénéficiaire: EVAX is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: EVAX is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accélération de la croissance: Unable to compare EVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: EVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement des fonds propres
ROE élevé: EVAX has a negative Return on Equity (-1213.49%), as it is currently unprofitable.